John Gubatan1, Shuji Mitsuhashi2, Talia Zenlea2, Laura Rosenberg2, Simon Robson2, Alan C Moss2. 1. Department of Medicine, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Electronic address: jgubatan@bidmc.harvard.edu. 2. Department of Medicine, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND & AIMS: Vitamin D levels have been associated with disease activity in patients with ulcerative colitis (UC), but it is unclear whether they affect the risk of disease relapse. We sought to determine the association between baseline vitamin D levels during a period of clinical remission and risk of subsequent UC relapse. METHODS: We performed a physician-blinded prospective study of 70 patients with UC in clinical remission followed up after a surveillance colonoscopy at a tertiary academic medical center. Serum samples were collected at the time of colonoscopy and baseline endoscopic and histologic activity were determined. Levels of 25-hydroxy-vitamin D were measured using an enzyme-linked immunosorbent assay. The primary outcome was rate of clinical relapse, determined over 12 months. RESULTS: The mean baseline vitamin D level was lower among patients with relapse (29.5 ng/mL) than without (50.3 ng/mL) (P = .001). Remission vitamin D level (≤35 ng/mL) was associated with a risk of clinical relapse (odds ratio, 1.25; 95% confidence interval [CI], 1.01-1.56; P = .044) over 12 months, independent of endoscopic or histologic grade at enrollment. A receiver operating characteristic curve of vitamin D levels for the outcome of relapse had an area under the curve of 0.72; and a serum level of 35 ng/mL or less had a sensitivity of 70% (95% CI, 46%-88%) and a specificity of 74% (95% CI 57%-83%) for predicting risk of clinical relapse. CONCLUSIONS: Serum levels of vitamin D of 35 ng/mL or less during periods of clinical remission increase the risk of UC relapse. Clinical trials to obtain vitamin D levels higher than this threshold should be considered.
BACKGROUND & AIMS:Vitamin D levels have been associated with disease activity in patients with ulcerative colitis (UC), but it is unclear whether they affect the risk of disease relapse. We sought to determine the association between baseline vitamin D levels during a period of clinical remission and risk of subsequent UC relapse. METHODS: We performed a physician-blinded prospective study of 70 patients with UC in clinical remission followed up after a surveillance colonoscopy at a tertiary academic medical center. Serum samples were collected at the time of colonoscopy and baseline endoscopic and histologic activity were determined. Levels of 25-hydroxy-vitamin D were measured using an enzyme-linked immunosorbent assay. The primary outcome was rate of clinical relapse, determined over 12 months. RESULTS: The mean baseline vitamin D level was lower among patients with relapse (29.5 ng/mL) than without (50.3 ng/mL) (P = .001). Remission vitamin D level (≤35 ng/mL) was associated with a risk of clinical relapse (odds ratio, 1.25; 95% confidence interval [CI], 1.01-1.56; P = .044) over 12 months, independent of endoscopic or histologic grade at enrollment. A receiver operating characteristic curve of vitamin D levels for the outcome of relapse had an area under the curve of 0.72; and a serum level of 35 ng/mL or less had a sensitivity of 70% (95% CI, 46%-88%) and a specificity of 74% (95% CI 57%-83%) for predicting risk of clinical relapse. CONCLUSIONS: Serum levels of vitamin D of 35 ng/mL or less during periods of clinical remission increase the risk of UC relapse. Clinical trials to obtain vitamin D levels higher than this threshold should be considered.
Authors: Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin Journal: Science Date: 2006-02-23 Impact factor: 47.728
Authors: Talat Bessissow; Bart Lemmens; Marc Ferrante; Raf Bisschops; Kristel Van Steen; Karel Geboes; Gert Van Assche; Séverine Vermeire; Paul Rutgeerts; Gert De Hertogh Journal: Am J Gastroenterol Date: 2012-11-13 Impact factor: 10.864
Authors: Ashwin N Ananthakrishnan; Hamed Khalili; Leslie M Higuchi; Ying Bao; Joshua R Korzenik; Edward L Giovannucci; James M Richter; Charles S Fuchs; Andrew T Chan Journal: Gastroenterology Date: 2011-12-09 Impact factor: 22.682
Authors: Alex Ulitsky; Ashwin N Ananthakrishnan; Amar Naik; Sue Skaros; Yelena Zadvornova; David G Binion; Mazen Issa Journal: JPEN J Parenter Enteral Nutr Date: 2011-05 Impact factor: 4.016
Authors: S P Jørgensen; J Agnholt; H Glerup; S Lyhne; G E Villadsen; C L Hvas; L E Bartels; J Kelsen; L A Christensen; J F Dahlerup Journal: Aliment Pharmacol Ther Date: 2010-05-11 Impact factor: 8.171
Authors: Weicheng Liu; Yunzi Chen; Maya Aharoni Golan; Maria L Annunziata; Jie Du; Urszula Dougherty; Juan Kong; Mark Musch; Yong Huang; Joel Pekow; Changqing Zheng; Marc Bissonnette; Stephen B Hanauer; Yan Chun Li Journal: J Clin Invest Date: 2013-08-15 Impact factor: 14.808
Authors: Joost Smolders; Mariëlle Thewissen; Evelyn Peelen; Paul Menheere; Jan Willem Cohen Tervaert; Jan Damoiseaux; Raymond Hupperts Journal: PLoS One Date: 2009-08-13 Impact factor: 3.240
Authors: Vishal Sharma; Harshal S Mandavdhare; Amit Kumar; Ravi Sharma; Naresh Sachdeva; Kaushal K Prasad; Surinder S Rana Journal: Ther Adv Infect Dis Date: 2017-05-25
Authors: Jeffrey S Hyams; Sonia Davis Thomas; Nathan Gotman; Yael Haberman; Rebekah Karns; Melanie Schirmer; Angela Mo; David R Mack; Brendan Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; David J Keljo; James Markowitz; Susan S Baker; Joel Rosh; Robert N Baldassano; Ashish Patel; Marian Pfefferkorn; Anthony Otley; Melvin Heyman; Joshua Noe; Maria Oliva-Hemker; Paul A Rufo; Jennifer Strople; David Ziring; Stephen L Guthery; Boris Sudel; Keith Benkov; Prateek Wali; Dedrick Moulton; Jonathan Evans; Michael D Kappelman; M Alison Marquis; Francisco A Sylvester; Margaret H Collins; Suresh Venkateswaran; Marla Dubinsky; Vin Tangpricha; Krista L Spada; Bradley Saul; Jessie Wang; Jose Serrano; Kevin Hommel; Urko M Marigorta; Greg Gibson; Ramnik J Xavier; Subra Kugathasan; Thomas Walters; Lee A Denson Journal: Lancet Date: 2019-03-29 Impact factor: 79.321
Authors: John Gubatan; Shuji Mitsuhashi; Maria Serena Longhi; Talia Zenlea; Laura Rosenberg; Simon Robson; Alan C Moss Journal: Cytokine Date: 2018-01-08 Impact factor: 3.861
Authors: Shilpa Grover; Michael Dougan; Kevin Tyan; Anita Giobbie-Hurder; Steven M Blum; Jeffrey Ishizuka; Taha Qazi; Rawad Elias; Kruti B Vora; Alex B Ruan; William Martin-Doyle; Michael Manos; Lauren Eastman; Meredith Davis; Maria Gargano; Rizwan Haq; Elizabeth I Buchbinder; Ryan J Sullivan; Patrick A Ott; F Stephen Hodi; Osama E Rahma Journal: Cancer Date: 2020-06-22 Impact factor: 6.860
Authors: John Gubatan; Gillian A Mehigan; Fernando Villegas; Shuji Mitsuhashi; Maria Serena Longhi; Grace Malvar; Eva Csizmadia; Simon Robson; Alan C Moss Journal: Inflamm Bowel Dis Date: 2020-05-12 Impact factor: 5.325